Growing hormone

Growth hormone (GH) is a peptide hormone that plays a crucial role in regulating growth, metabolism, and development in children and adults. In medical contexts, growth hormone therapy is commonly used to treat growth disorders, such as growth hormone deficiency (GHD) and conditions like Turner syndrome or Prader-Willi syndrome. However, there is increasing interest and speculation about whether growth hormone could have potential benefits for children with autism, particularly in terms of improving brain function, behavior, or developmental outcomes. Some researchers believe that because GH can influence brain growth and cognitive development, it might help improve some autism symptoms, particularly related to cognitive function or social development. There is very little research directly investigating the use of growth hormone therapy in children with autism. Most studies focus on GH therapy in children with growth hormone deficiency or other genetic conditions that may be associated with autism-like symptoms (e.g., Prader-Willi syndrome).

Some early studies on IGF-1 have shown potential benefits in children with Phelan-McDermid syndrome, a genetic condition associated with autism. These studies suggest that IGF-1 may improve social behavior and language skills in children with this condition, but the research is limited to very specific genetic subtypes of autism and is not applicable to all children with autism. GH therapy can have side effects, particularly when used inappropriately or in individuals who do not have GH deficiency. Common side effects include joint pain, fluid retention, increased risk of diabetes, and potential issues with bone growth.
The long-term safety of growth hormone therapy, especially when used in children without a clear medical indication, is not well understood. Some studies suggest that long-term GH therapy could increase the risk of certain cancers or metabolic disorders, although this is still being researched. Administering growth hormone to children with autism who do not have a diagnosed GH deficiency or related condition raises ethical concerns. GH therapy is expensive, invasive (involving regular injections), and carries risks that may outweigh any potential, speculative benefits.